Boston Scientific
Advancing science for life™

Leading the way in longevity

Boston Scientific ICDs deliver proven long-lasting battery life, reducing risk and cost for better patient outcomes.

Longest

observed longevity across all types of devices[1]

2-3 years

greater longevity than other brands[1]

45% cost

reduction in single-chamber devices at 12 yrs[2]

43,000

patients analysed[1]

20 years

of real-world data[1]

Biventricular (RA, RV, LV) ICDs[1]



"The superior performance of Boston Scientific devices may reduce the frequency of generator replacements."[3]

Every ICD replacement carries risk – infection, procedural complications. That's why longevity isn't just a technical specification; it's a clinical advantage. A new independent publication[1] analysing over 40,000 ICDs demonstrates that Boston Scientific devices outlast all other manufacturers, meaning fewer interventions, fewer risks, and a better experience for patients and providers.

Why longevity matters:

Better for patients – Patients are getting devices earlier, living longer and prefer longer lasting devices

- **35-40%** of patients with ICD or CRT-D < 65 years old[4]
- **80%** of mildly symptomatic CRT-D patients are living 7 years post implant[5]
- **40%** of ICD patients are living 10 years post implant[6]

Reduces the risk of procedural complications – More replacements are associated with higher infection and lead complications risks[7]



Reduce costs of therapy over time – Boston Scientific ICDs have the lower cost of therapy over time[2]



References

1. Freeman *et al*. Variability in implantable cardioverter-defibrillator battery longevity. Heart Rhythm, Volume 23, Issue 5, P1162-1171, May 2026 – https://doi.org/10.1016/j.hrthm.2025.05.031
2. EP Edge Journal Watch Issue 25, June 2026 Redefining EP Endpoints: LAAC After Ablation, AF Burden, PFA Durability, and ICD Longevity and Strategy – https://epedge.substack.com/p/ep-edge-journal-watch-issue-25-june
3. Nishino K, Temma T, Watanabe *et al*. Battery Longevity in Modern Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy-Defibrillators. J Arrhythm. 2025 Aug 15;41(4):e70175. doi: 10.1002/joa3.70175.
4. Novation - Cardiovascular Watch: CRM Device Battery Life, May 2012 – https://www.novationco.com/other/apps/devicebattery/
5. Goldenberg I, Kutyifa V, Klein H, *et al*. Survival with Cardiac-Resynchronization Therapy in Mild Heart Failure. NEJM 370;18: 1694-1701. Seven-year survival relates to patients with left bundle branch block with QRS ≥ 130 ms, EF ≤ 30% NYHA Class I or II ischemic or NYHA Class II non-ischemic heart failure.
6. Hauser. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. JACC 2005; 45; 2022-5.
7. Borleffs CJ, Thijssen J, Mihaly K, van Rees JB, van Erven L, *et al*. Recurrent Implantable Cardioverter-Defibrillator Replacement is Associated with an Increasing Risk of Pocket-Related Complications. PACE 2010;33:1013–1019.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

Boston Scientific
Advancing science for life™

www.bostonscientific.com

© 2026 Boston Scientific Corporation or its affiliates. All rights reserved.

CRM-2537306-AA

CE 2797